Serum free 5-methoxypsoralen fraction in health and psoriasis: relationship with human serum albumin concentration

Abstract

Human serum albumin is known to be the main carrier of 5-methoxypsoralen (5-MOP) in serum. As hypoalbuminaemia may occur in psoriasis with inflammatory syndrome, variability of the free 5-MOP fraction in serum can be expected. The free 5-MOP fraction was determined by equilibrium dialysis in serum samples obtained from 18 psoriatic patients and 18 control subjects. The median free 5-MOP fraction was not significantly different in the psoriatic group (fu = 4.75%) than in the control group (fu = 5%). However, there was a significantly larger variability of the free fraction in the psoriatic group (2.7 to 8.6%) than in the healthy group (3.2 to 6.8%) (p = 0.002). The binding index of 5-MOP (ratio of bound to free concentrations) was correlated with human serum albumin level (r = 0.784). This work confirms that the 5-MOP fraction in human serum is principally serum albumin dependent, as has been described with in vitro models. Free drug monitoring of 5-MOP is discussed.

Chromatographic determination of the association constant between 8-methoxypsoralen and modified β-cyclodextrin: protective effect of hydroxypropyl-β-cyclodextrin on 8-methoxypsoralen toxicity in human keratinocytes

“…Psoralens are regularly used in therapy, in combination with ultraviolet A (UVA) light irradiation to treat skin diseases, such as psoriasis, vitiligo and mycosis fungoides [1][2][3][4][5]. In the skin, the combination of psoralens and UVA, also known PUVA, is a potent modulator of epidermal cell growth and differentiation [6,7].…”